How does sermorelin differ from growth hormone itself?

Sermorelin does not deliver growth hormone directly. It stimulates the pituitary gland to release the body's own GH through the normal GHRH receptor pathway. Exogenous growth hormone bypasses the pituitary and can suppress natural GH production; sermorelin preserves the pituitary's role and the pulsatile rhythm of GH secretion.

Why was Geref discontinued if it was FDA-approved?

Serono withdrew Geref and Geref Diagnostic from the US market around 2008. The withdrawal was a commercial decision tied to patent expiry rather than a response to safety or efficacy problems. Once the compound was no longer patent-protected, maintaining a branded product was not economically practical for the originator.

How does sermorelin compare with CJC-1295?

Both are GHRH analogs that stimulate pituitary GH release, but they differ substantially in pharmacokinetics. Sermorelin has a half-life of roughly 10 to 20 minutes, requiring frequent administration to maintain effect. CJC-1295 carries a Drug Affinity Complex modification that lets it bind serum albumin, extending its half-life to approximately one week. Tesamorelin, which is FDA-approved for a specific indication, sits between the two in terms of duration.

Is sermorelin banned by WADA?

Yes. GHRH and its analogs are prohibited at all times under section S2 of the World Anti-Doping Agency Prohibited List. Sermorelin, as a GHRH analog, is covered by this prohibition. Athletes subject to anti-doping rules face consequences for its use in or out of competition.

Growth Hormone Axis

Sermorelin

Synthetic 29 amino acid fragment of human growth hormone-releasing hormone, once FDA-approved for pediatric GH deficiency.

Also known as: GHRH(1-29), Geref, Sermorelin acetate

Published: April 26, 2026•Updated: April 26, 2026

Research use only. This page is an informational reference about a compound that may be available as a research chemical. Material sold for research is not cleared for human administration and is not a substitute for medical advice or an approved medication. See safety notes below.

Sermorelin is a synthetic peptide that reproduces the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone through the same receptor pathway as native GHRH. The compound was approved by the FDA in the 1990s under the brand name Geref and was later discontinued from the US market after patent expiry. It remains one of the most studied GHRH analogs in the peer-reviewed literature.

Key facts

Class: GHRH analog (N-terminal fragment)
Structure: 29 amino acid peptide matching GHRH(1-29)-NH2
Originator: Serono (now EMD Serono)
Regulatory status: FDA approved as Geref (1997); discontinued from US market around 2008 after patent expiry
Half-life: Approximately 10 to 20 minutes; shorter than CJC-1295 due to lack of albumin-binding modification

What is sermorelin?

Sermorelin is the synthetic acetate salt of a 29 amino acid peptide that represents the N-terminal active fragment of human growth hormone-releasing hormone. Native GHRH is a 44 amino acid hypothalamic hormone; the first 29 residues are sufficient for full receptor binding and biological activity at the pituitary level. Sermorelin retains this activity while being shorter and therefore easier to synthesize than full-length GHRH.

The compound was developed by Serono and approved by the FDA in 1997 under the brand name Geref for the treatment of growth hormone deficiency in children. A second formulation, Geref Diagnostic, was approved for use as a provocative test to assess the pituitary's capacity to secrete growth hormone. Both formulations were eventually discontinued from the US market around 2008 after the compound's patent position expired, not because of safety or efficacy concerns.

Mechanism of action

Sermorelin binds to the GHRH receptor on somatotroph cells in the anterior pituitary gland. Receptor activation triggers a cascade that increases intracellular cyclic AMP, which in turn stimulates synthesis and pulsatile secretion of growth hormone. Because sermorelin works through the normal pituitary pathway rather than introducing exogenous GH directly, the pituitary's own feedback mechanisms remain operative.

•Binds GHRH receptor on pituitary somatotroph cells
•Stimulates cyclic AMP production and downstream GH gene expression
•Triggers pulsatile GH release that follows the body's normal physiological rhythm
•Does not suppress endogenous GHRH production the way exogenous growth hormone can

Clinical and regulatory history

The FDA approved sermorelin acetate (Geref) in 1997 for the long-term treatment of growth failure in children due to inadequate secretion of endogenous growth hormone. The Geref Diagnostic formulation was approved for evaluating GH secretory capacity in adults and children with suspected growth hormone deficiency. Both approvals established a documented clinical safety and tolerability profile in pediatric populations.

After Serono's patent on sermorelin lapsed, the branded product was withdrawn from the US market. Compounding pharmacies in the United States have prepared sermorelin under specific regulatory frameworks, and the compound has continued to be studied in contexts including aging and body composition. It has also been used as a reference compound in research comparing GHRH analogs, including tesamorelin and CJC-1295, which were developed in part to extend the short half-life that limits sermorelin's convenience.

Comparison with other GHRH analogs

Sermorelin's short half-life of roughly 10 to 20 minutes is its main pharmacological limitation compared with later GHRH analogs. Tesamorelin, approved by the FDA for HIV-associated lipodystrophy, uses a trans-3-hexenoic acid modification at the N-terminus to improve stability against enzymatic cleavage while retaining daily administration. CJC-1295 adds a Drug Affinity Complex maleimide group that covalently binds serum albumin, dramatically extending the half-life to approximately one week.

Where sermorelin produces a transient GH pulse that decays within an hour, the longer-acting analogs maintain more sustained receptor stimulation. Researchers studying the downstream effects of GHRH signaling sometimes prefer sermorelin precisely because its kinetics allow clear observation of GH pulse onset and return to baseline.

Safety and regulatory context

The safety profile of sermorelin was characterized during its FDA-approved clinical use in children. Common adverse effects in clinical trials included injection site reactions and occasional flushing. As a compound that acts through the pituitary axis, it shares theoretical risks with other GH-stimulating agents, including potential effects in individuals with undiagnosed pituitary tumors.

The World Anti-Doping Agency prohibits GHRH and its analogs under section S2 of the Prohibited List at all times. Sermorelin, as a GHRH analog, falls under this prohibition, and athletes subject to WADA rules face anti-doping consequences for its use. Material sold as research sermorelin is intended strictly for laboratory use and is not cleared for human administration.

Research sourcing

Sermorelin is listed by our research partner, GLP1 Research Lab, which supplies lyophilized peptides for laboratory use. Listings include product identifiers relevant to research documentation.

View Sermorelin listing at GLP1 Research Lab

Affiliate partnership. Metabolic Playbook may earn a commission on purchases made through this link at no additional cost to the researcher.